Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00048971
Other study ID # CALGB-60102
Secondary ID CALGB-60102NCCTG
Status Completed
Phase N/A
First received November 12, 2002
Last updated July 1, 2016
Start date April 2002
Est. completion date November 2006

Study information

Verified date July 2016
Source Alliance for Clinical Trials in Oncology
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

RATIONALE: Genetic testing may help predict how patients will respond to chemotherapy drugs and may help doctors plan more effective treatment with fewer side effects.

PURPOSE: Genetic study to determine how genes affect the severity of diarrhea in patients with stage III colon cancer who are receiving chemotherapy.


Description:

OBJECTIVES:

- Determine whether the presence of a 7 allele at the UGT1A1 locus is associated with either grade 3-4 diarrhea or grade 4 neutropenia in patients with stage III colon cancer after treatment with irinotecan, fluorouracil, and leucovorin calcium.

- Determine whether polymorphisms in the TS enhancer and/or MTHFR gene are associated with grade 3-4 diarrhea in these patients after treatment with fluorouracil and leucovorin calcium.

- Determine whether polymorphisms in UGT1A1, TS, MTHFR, CYP3A4, or CYP3A5 are associated with either grade 3-4 diarrhea or grade 4 neutropenia in these patients after treatment with irinotecan, fluorouracil, and leucovorin calcium.

OUTLINE: Patients are stratified according to prior therapy (irinotecan, fluorouracil, and leucovorin calcium vs fluorouracil and leucovorin calcium) and prior toxic effects (grade 3-4 diarrhea vs grade 4 neutropenia vs grade 1 or lower diarrhea AND grade 2 or lower neutropenia).

Patients undergo collection of blood specimens for polymerase chain reaction and restriction fragment length polymorphism analysis. Genotyping assays are performed to determine UGT1A1 promoter genotyping, UGT1A1 coding polymorphisms, TS promoter polymorphisms, and MTHFR polymorphisms.


Recruitment information / eligibility

Status Completed
Enrollment 308
Est. completion date November 2006
Est. primary completion date November 2006
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed stage III adenocarcinoma of the colon

- Enrolled on CALGB-89803 and must fall into 1 of the following categories:

- Received irinotecan, fluorouracil, and leucovorin calcium and experienced at least 1 of the following:

- Grade 3-4 diarrhea

- Grade 4 neutropenia

- Grade 1 or lower diarrhea AND grade 2 or lower neutropenia

- Received fluorouracil and leucovorin calcium and experienced at least 1 of the following:

- Grade 3-4 diarrhea

- Grade 1 or lower diarrhea AND grade 2 or lower neutropenia

PATIENT CHARACTERISTICS:

Age

- 18 and over

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Genetic:
mutation analysis

polymorphic microsatellite marker analysis


Locations

Country Name City State
Canada McGill University Montreal Quebec
Puerto Rico University of Puerto Rico School of Medicine Medical Sciences Campus San Juan
United States Northeast Alabama Regional Medical Center Anniston Alabama
United States Veterans Affairs Medical Center - Asheville Asheville North Carolina
United States Marlene and Stewart Greenebaum Cancer Center, University of Maryland Baltimore Maryland
United States Veterans Affairs Medical Center - Baltimore Baltimore Maryland
United States Green Mountain Oncology Group Bennington Vermont
United States Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Boston Massachusetts
United States Roswell Park Cancer Institute Buffalo New York
United States Veterans Affairs Medical Center - Buffalo Buffalo New York
United States Vermont Cancer Center at University of Vermont Burlington Vermont
United States Cooper University Hospital Camden New Jersey
United States Lineberger Comprehensive Cancer Center, UNC Chapel Hill North Carolina
United States Martha Jefferson Hospital Charlottesville Virginia
United States Louis A. Weiss Memorial Hospital Chicago Illinois
United States MBCCOP - University of Illinois at Chicago Chicago Illinois
United States University of Chicago Cancer Research Center Chicago Illinois
United States Veterans Affairs Medical Center - Chicago (Westside Hospital) Chicago Illinois
United States Ellis Fischel Cancer Center at University of Missouri - Columbia Columbia Missouri
United States Veterans Affairs Medical Center - Columbia (Truman Memorial) Columbia Missouri
United States Arthur G. James Cancer Hospital - Ohio State University Columbus Ohio
United States NorthEast Oncology Associates Concord North Carolina
United States Simmons Cancer Center at University of Texas Southwestern Medical Center - Dalas Dallas Texas
United States Veterans Affairs Medical Center - Dallas Dallas Texas
United States CCOP - Geisinger Clinic and Medical Center Danville Pennsylvania
United States Duke Comprehensive Cancer Center Durham North Carolina
United States Veterans Affairs Medical Center - Durham Durham North Carolina
United States Elmhurst Hospital Center Elmhurst New York
United States Veterans Affairs Medical Center - Fargo Fargo North Dakota
United States Cape Fear Valley Health System Fayetteville North Carolina
United States Broward General Medical Center Fort Lauderdale Florida
United States Fort Wayne Medical Oncology and Hematology, Incorporated Fort Wayne Indiana
United States CCOP - St. Vincent Hospital Cancer Center, Green Bay Green Bay Wisconsin
United States Memorial Regional Hospital Comprehensive Cancer Center Hollywood Florida
United States St. Mary's Medical Center Huntington West Virginia
United States Holden Comprehensive Cancer Center at University of Iowa Iowa City Iowa
United States Queens Cancer Center of Queens Hospital Jamaica New York
United States Lenoir Memorial Hospital Cancer Center Kinston North Carolina
United States Rebecca and John Moores UCSD Cancer Center La Jolla California
United States CCOP - Southern Nevada Cancer Research Foundation Las Vegas Nevada
United States Veterans Affairs Medical Center - Las Vegas Las Vegas Nevada
United States Norris Cotton Cancer Center at Dartmouth Medical School Lebanon New Hampshire
United States Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center Los Angeles California
United States Baptist Hospital East - Louisville Louisville Kentucky
United States CCOP - North Shore University Hospital Manhasset New York
United States North Shore University Hospital Manhasset New York
United States CCOP - Mount Sinai Medical Center Miami Beach Florida
United States University of Minnesota Cancer Center Minneapolis Minnesota
United States Veterans Affairs Medical Center - Minneapolis Minneapolis Minnesota
United States Memorial Sloan-Kettering Cancer Center New York New York
United States Mount Sinai Medical Center, NY New York New York
United States New York Weill Cornell Cancer Center at Cornell University New York New York
United States CCOP - Christiana Care Health Services Newark Delaware
United States Virginia Oncology Associates - Norfolk Norfolk Virginia
United States University of Nebraska Medical Center Omaha Nebraska
United States Florida Hospital Cancer Institute Orlando Florida
United States FirstHealth Moore Regional Hospital Pinehurst North Carolina
United States Western Pennsylvania Hospital Pittsburgh Pennsylvania
United States Lifespan: The Miriam Hospital Providence Rhode Island
United States Ministry Medical Group - Northern Region Rhinelander Wisconsin
United States MBCCOP - Massey Cancer Center Richmond Virginia
United States West Suburban Center for Cancer Care River Forest Illinois
United States Oncology and Hematology Associates of Southwest Virginia, Inc. Roanoke Virginia
United States Saint Anthony Medical Center Rockford Illinois
United States Lakeland Medical Center - St. Joseph Saint Joseph Michigan
United States Barnes-Jewish Hospital Saint Louis Missouri
United States Missouri Baptist Cancer Center Saint Louis Missouri
United States Siteman Cancer Center Saint Louis Missouri
United States Veterans Affairs Medical Center - San Diego San Diego California
United States UCSF Comprehensive Cancer Center San Francisco California
United States Veterans Affairs Medical Center - San Francisco San Francisco California
United States CCOP - Northern Indiana CR Consortium South Bend Indiana
United States CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C. Syracuse New York
United States State University of New York - Upstate Medical University Syracuse New York
United States Veterans Affairs Medical Center - Syracuse Syracuse New York
United States Lombardi Cancer Center of Georgetown University Medical Center Washington District of Columbia
United States Veterans Affairs Medical Center - Washington, DC Washington District of Columbia
United States Walter Reed Army Medical Center Washington District of Columbia
United States Palm Beach Cancer Institute West Palm Beach Florida
United States Veterans Affairs Medical Center - White River Junction White River Junction Vermont
United States New Hanover Regional Medical Center Wilmington North Carolina
United States CCOP - Southeast Cancer Control Consortium Winston-Salem North Carolina
United States Comprehensive Cancer Center at Wake Forest University Winston-Salem North Carolina
United States University of Massachusetts Memorial Medical Center - University Campus Worcester Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Alliance for Clinical Trials in Oncology National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Canada,  Puerto Rico, 

Outcome

Type Measure Description Time frame Safety issue
Primary response Up to 4 years No
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A